# Cytochroma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cytochroma

- Industry: Pharmaceuticals
- Headquarters: Markham, Canada
- Website: www.cytochroma.com
- Total disclosed funding: $59M
- Latest round: Series C (Jul 30, 2008)
- Investors on record: 13

## About

Cytochroma is a clinical stage specialty pharmaceutical company. It designs, develops, and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD).

## Funding rounds

- Series C, Jul 30, 2008, $45M — VenGrowth Capital Partners, BDC Capital, GrowthWorks Capital, CDPQ, T2C2, VentureLink Funds, MP Healthcare Venture Management, Canadian Medical Discoveries Fund Inc., Novo Holdings A/S
- Series B, Dec 4, 2002, $4.1M — VenGrowth Capital Partners
- Series B, Dec 18, 2001, $2.2M — GeneChem, VentureLink, Canadian Medical Discoveries Fund Inc., Business Development Bank of Canada, Novo Holdings
- Series B, Oct 29, 2001, $7.6M — CDPQ, T2C2

## Investors

- CDPQ — Series B, Series C
- T2C2 (https://capitalatlas.ai/funds/t2c2) — Series B, Series C
- GeneChem (https://capitalatlas.ai/funds/genechem) — Series B
- VentureLink — Series B
- Canadian Medical Discoveries Fund Inc. — Series B, Series C
- Business Development Bank of Canada — Series B
- Novo Holdings — Series B
- VenGrowth Capital Partners (https://capitalatlas.ai/funds/vengrowth-capital-partners) — Series B, Series C
- BDC Capital (https://capitalatlas.ai/funds/bdc-capital) — Series C
- GrowthWorks Capital (https://capitalatlas.ai/funds/growthworks-capital) — Series C
- VentureLink Funds — Series C
- MP Healthcare Venture Management (https://capitalatlas.ai/funds/mp-healthcare-venture-management) — Series C
- Novo Holdings A/S — Series C